Biogen (BIIB) Inventory (2009 - 2026)

Biogen (BIIB) has reported Inventory for 18 consecutive years, with $1.9 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Inventory fell 14.29% year-over-year to $1.9 billion; the TTM figure through Mar 2026 stood at $1.9 billion (down 14.29% YoY), while the FY2025 annual figure was $2.2 billion, down 11.88% from the prior year.
• Inventory came in at $1.9 billion for Q1 2026 at Biogen, down from $2.2 billion in the prior quarter.
• The five-year high for Inventory was $3.0 billion in Q3 2023, with the low at $1.2 billion in Q1 2022.
• Average Inventory over 5 years is $2.0 billion, with a median of $2.2 billion recorded in 2025.
• Across the five-year window, Inventory surged 116.9% in 2023 and fell 17.21% in 2024, its largest moves.
• Year by year, Inventory stood at $1.3 billion in 2022, then soared by 87.99% to $2.5 billion in 2023, then decreased by 2.65% to $2.5 billion in 2024, then slipped by 11.88% to $2.2 billion in 2025, then fell by 10.11% to $1.9 billion in 2026.
• According to Business Quant data, Inventory over the past three periods registered $1.9 billion, $2.2 billion, and $2.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.